What is HC Wainwright's Estimate for HURA Q1 Earnings?

Key Points

• HC Wainwright expects TuHURA Biosciences to report Q1 2027 EPS of ($0.15), with projections of ($0.15) in Q2 and Q3, ($0.16) in Q4, and ($0.61) for full-year 2027.
• Analyst sentiment is generally positive: five analysts rate HURA a Buy and one rates it a Sell, producing a consensus “Moderate Buy” rating and an average price target of $9.00.
• TuHURA’s latest quarterly results beat expectations, reporting a loss of ($0.14) per share versus the consensus loss estimate of ($0.15); the stock opened at $2.28 and has gained 5.6%.

TuHURA Biosciences, Inc. (NASDAQ:HURA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 earnings estimates for TuHURA Biosciences in a research note issued on Wednesday, August 19th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($0.15) for the quarter. The consensus estimate for TuHURA Biosciences' current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for TuHURA Biosciences' Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($0.61) EPS.

Several other research firms have also weighed in on HURA. Citigroup initiated coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set an "outperform" rating on the stock. Citizens Jmp reaffirmed a "market outperform" rating and set a $9.00 price target on shares of TuHURA Biosciences in a research report on Tuesday. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of TuHURA Biosciences in a report on Friday, July 17th. Finally, Wall Street Zen cut TuHURA Biosciences from a "hold" rating to a "sell" rating in a research report on Sunday, May 31st. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $9.00.

TuHURA Biosciences Stock Up 5.6%

TuHURA Biosciences stock opened at $2.28 on Thursday. The company has a current ratio of 0.18, a quick ratio of 1.15 and a debt-to-equity ratio of 0.20. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $3.43. The company has a fifty day simple moving average of $2.29 and a 200 day simple moving average of $2.04. The company has a market cap of $145.30 million, a P/E ratio of -4.22 and a beta of -0.01.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01.

Hedge Funds Weigh In On TuHURA Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Sanctuary Advisors LLC acquired a new position in shares of TuHURA Biosciences in the second quarter worth approximately $49,000. Ieq Capital LLC bought a new position in TuHURA Biosciences during the second quarter worth $99,000. Invst LLC acquired a new position in TuHURA Biosciences in the second quarter valued at $99,000. Cetera Investment Advisers bought a new stake in TuHURA Biosciences during the first quarter valued at $251,000. Finally, WealthShield Partners LLC bought a new stake in TuHURA Biosciences during the second quarter valued at $214,000. Institutional investors and hedge funds own 0.62% of the company's stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company's core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA's approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source